1. j, Plasma active GIP (1–42) and GLP1 (7–36). In h and j, n = 6 mice per group; mean ± s.e.m.; *P < 0.05; n.s., non-significant by two-tailed Student’s t-test. Source data Extended Data Figure 5 Hepatocyte-specific silencing of DPP4 improves ...
Taken together, our results demonstrate a role of DPP4 in regulating GABAergic transmission via the GLP-1/GLP-1R pathway. These findings indicated that DPP4 may represent a novel therapeutic strategy and target for FS.doi:10.1016/j.bcp.2018.08.004Zhang Yusong...
Incretin hormones, principally glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), contribute to control of islet function. Their bioactivity is regulated by the enzymatic activity of dipeptidyl peptidase-4 (DPP-4), a widely expressed serine protease (Deacon, 2004...
The present invention refers to a compound therapy including DP4 inhibitor and SGLT inhibitor. The current combination of inventions has led to an increase in plasma GLP-1 levels, which is effective in the prevention or treatment of diabetes and diabetes related diseases. ILO Convention No. 14: ...
3.2.1. Physiological Role of DPP4 in Glycemic Control DPP4 is involved in the endogenous control of glycemia, being physiologically or pharmacology related to the degradation of glucagon, glucagon-like peptide-1 (GLP-1) and -2 (GLP-2), gastric inhibitory peptide or glucose-dependent insulinotropic...
[13]. DPP4 can enzymatically truncate proteins containing either L-proline or L-alanine at the penultimate position, and for this reason plays a major role in glucose metabolism where it regulates glucagon-like peptide-1 (GLP1) and gastric inhibitory protein (GIP) [14]. Accordingly, several ...
As insulin resistance is a common problem in patients with type 2 DM, it is of major importance to clarify whether GLP-1 and, accordingly, GLP-1-based drugs (GLP-1 analogues, see below) have the capacity to exert their beneficial effects not only indirectly via insulin and glucagon, but ...